Article Sidebar

Submitted
Mar 30, 2021
Published
Mar 30, 2021
Download
PDF
Statistic
Read Counter : 47 Download : 41

Main Article Content

Abstract

Background


One of the commonest non-communicable disease in nearly all age groups and particularly in old age is diabetes mellitus. For most of the newly diagnosed cases of type 2 diabetes mellitus and for initial treatment, many drugs are used as single drug therapy. Due to not much availability of information for the choice of initial single drug therapy for type 2 diabetes mellitus, the present study is undertaken.


Objectives


To find any differences in the efficacy and tolerability of metformin and glibenclamide for initial therapy of type 2 diabetes mellitus.


Materials and methods


In this study, 100 pateints are taken with type 2 diabetes mellitus. Fifty patients were given metformin and fifty were given glibenclamide, once daily or twice daily accordingly, after the meals. Random blood glucose level is recorded daily for one month using standard techniques. The data collected was analyzed statistically using descriptive statistics. And patients are followed for any adverse effects and compliance.


Results


At the end of the study, 90% subjects in metformin group showed normal blood glucose level as compared 76% in glibenclamide. Metformin seems to be better than glibenclamide in controlling blood glucose level. More side effects are seen in metformin group. Patient compliance was good with all study groups.


Interpretation and conclusion


It appears that metformin is better than glibenclamide for initial therapy of type 2 diabetes mellitus as it decreases the blood glucose level more effectively than glibenclamide in single drug therapy.

Keywords

Diabetes mellitus Metformin Glibenclamide

Article Details

How to Cite
Dr. Syed Wasif, & Dr. Ashfaq Ahmed2. (2021). Metformin v/s glibenclamide : for intial therapy of type 2 diabetes mellitus in a tertiary care hospital, a comparative study, for efficacy and tolerability. International Journal of Research in Pharmacology & Pharmacotherapeutics, 8(1), 23-28. https://doi.org/10.61096/ijrpp.v8.iss1.2019.23-28
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. Tripati KD. Insulin, Oral Hypoglycaemic drugs and Glucagon. In. Essentials of Medical Pharmacology. Jaypee brothers medical publishers. 7, 2011.
  2. [2]. Sharma HL, Sharma KK. Insulin and Other Antidiabetic drugs. In: Principles of Pharmacology. Paras medical publisher. 2, 626- 640.
  3. [3]. Brunton LL, Chabner BA, Knollmann BC, editors. Endocrine Pancreas and Pharmacotherapy of Daibetes Mellitus and Hypoglycaemia. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13, 2017. New York: McGraw-Hill Companies.
  4. [4]. Ahlquist D, Camilleri M editors. Diabetes Mellitus. In: Harrisons: Principles of internal medicine. McGraw Hill companies: 19, 2016, 640-650.
  5. [5]. Katzung, B.G., Masters, S.B., and Trevor, A.J, Basic and Clinical Pharmacology. New York: Mc Graw-Hill Medical. 13, 2015.
  6. [6]. Rosenstock J, et al.Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 8(6), 2006, 650-60.
  7. [7]. American Diabetes Association, Diabetes Care 40(1), 2017, S11-S24.
  8. [8]. Barco SD, et al. Metformin: Multi-faceted protection against cancer. Oncotarget. 2(12), 2011, 896–917.
  9. [9]. Viollet B, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 122(6), 2012, 253–270.
  10. [10]. Morgan CL, et al. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab. 16(10), 2014, 977-83. doi: 10.1111/dom.12306. Epub 2014.
  11. [11]. Fung CSC, et al. Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients. Cardiovasc Diabetol. 14, 2015, 137.
  12. Mcphee SJ, Papadakis MA. Diabetes Mellitus and Hypoglycemia. In: Current Medical Diagnosis and Treatment.McGraw Hill companies: 2008.
  13. [12]. Jiang YF, et al. Comparative efficacy and safety of OADs in management of GDM: network meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 100(5), 2015, 2071-80. doi: 10.1210/jc.2014-4403. Epub 2015.
  14. [13]. Chang C, Sakaguchi M, Dolin P. Epidemiology of lactic acidosis in type 2 diabetes patients with metformin in Japan. Pharmacoepidemiol Drug Saf. 25(10), 2016, 1196–1203.
  15. [14]. Williams LK, et al. Differing Effects of Metformin on Glycemic Control by Race-Ethnicity. J Clin Endocrinol Metab. 99(9), 2014, 3160–3168.
  16. [15]. Lachin JM, et al. Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program. Diabetes. 56(4), 2007, 1153–1159.
  17. [16]. Rojas LBA, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 5, 2013, 6.
  18. [17]. Davidson JA, Sloan L. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview. Adv Ther. 34(1), 2017, 41–59.
  19. [18]. Tosi F, et al. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. Metabolism. 52(7), 2003, 862-7.
  20. [19]. Unnikrishnan R, Shah VN, Mohan V. Challenges in diagnosis and management of diabetes in the young.Clin Diabetes Endocrinol. 2, 2016, 18.
  21. [20]. Mcphee SJ, Papadakis MA. Diabetes Mellitus and Hypoglycemia. In: Current Medical Diagnosis and Treatment.McGraw Hill companies: 2008.
  22. [21]. Brunetti P, et al. Effects of two different glibenclamide dose-strengths in the fixed combination with metformin in patients with poorly controlled T2DM: a double blind, prospective, randomised, cross-over clinical trial. Diabetes Nutr Metab. 17(6), 2004, 350-7.
  23. [22]. Wang JS, et al. Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy. J Diabetes. 9(3), 2017, 248-255. doi: 10.1111/1753-0407.12406. Epub 2016.
  24. [23]. Sun J, et al. Deciphering Signaling Pathway Networks to Understand the Molecular Mechanisms of Metformin Action. PLoS Comput Biol. 11(6), 2015, e1004202.
  25. [24]. Gu S, et al. Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: A Meta-Analysis. PLoS One. 10(5), 2015, e0126704.
  26. [25]. Liang H, et al. Comparative efficacy and safety of oral antidiabetic drugs and insulin in treating gestational diabetes mellitus. Medicine (Baltimore). 96(38), 2017, e7939.
  27. [26]. Patterson AG, et al. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ. 350, 2015, h102.
  28. [27]. Hatoum D, McGowan EM. Recent Advances in the Use of Metformin: Can Treating Diabetes Prevent Breast Cancer?. Biomed Res Int. 2015, 548436.
  29. [28]. Lee KT, et al. Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus. Medicine (Baltimore). 96(28), 2017, e7507.
  30. [29]. Plata PA, et al. Metformin effects revisited. Diabetes Res Clin Pract. 95(1), 2012, 1–9.
  31. [30]. Haak T, et al. Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study. Int J Clin Pract. 67(12), 2013, 1283–1293.
  32. [31]. Satoskar RS, Rage NN, Bhandarkar SD. Insulin and Oral Hypoglycaemic drugs. In: Pharmacology and Pharmacotherapeutics. 22, 874 – 906.
  33. [32]. Garber A, et al. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 8(2), 2006, 156-63.
  34. [33]. Morgan CL, et al. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study. Diabetes Obes Metab. 16(10), 2014, 957-62. doi: 10.1111/dom.12302. Epub 2014.
  35. [34]. Nachum Z, et al. Glyburide versus Metformin and their Combination for the treatment of Gestational Diabetes Mellitus: A Randomized Study. Diabetes Care. 40(3), 2017, 332-337. doi: 10.2337/dc16-2307. Epub 2017.
  36. [35]. Jennifer N, Jose C. An upadate on the pharmacogenomics of metformin: progress, problems and potential. Pharmacogenomics. 15(4), 2014, 529–539. doi: 10.2217/pgs.14.21.
  37. [36]. Lee EY, et al. Association between Metformin Use and Risk of Lactic Acidosis or Elevated Lactate Concentration in Type 2 Diabetes. Yonsei Med J. 58(2), 2017, 312–318.
  38. [37]. Cefalu WT, et al. Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management. Diabetes Care 37(9), 2014, 2647–2659.
  39. [38]. Aschner P, et al. Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults. Clomb Med (cali). 47(2), 2016, 109–131.
  40. [39]. Joy NG, et al. Counterregulatory Responses to Hypoglycemia Differ between Glimepiride and Glyburide in Non Diabetic Individuals. Metabolism. 64(6), 2015, 729–737.
  41. [40]. Gorter KJ, et al. Diabetes: glycaemic control in type 2 (drug treatments). BMJ Clin Evid. 11, 2012, pii: 0609.
  42. [41]. Nachum Z, et al. Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study. Diabetes Care. 40(3), 2017, 332-337. doi: 10.2337/dc16-2307. Epub 2017.
  43. [42]. Setter SM, et al. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther. 25(12), 2003, 2991-3026.
  44. [43]. Inzucchi SE, et al. Metformin in Patients With Type 2 Diabetes and Kidney Disease. JAMA. 24-31, 2014, 312(24), 2668–2675.